63857-00-1Relevant articles and documents
Heptamethine indocyanine dye as well as preparation method and application thereof
-
Paragraph 0131-0136, (2021/10/05)
The invention provides a heptamethine indocyanine dye as well as a preparation method and an application thereof, and belongs to the technical field of fine chemical engineering. The heptamethine indocyanine dye provided by the invention has a structure a
Ligand taking indocyanine green derivative as carrier as well as preparation method and application of ligand
-
Paragraph 0212; 0215; 0220-0221; 0280; 0283; 0287-0288, (2021/06/23)
The invention discloses a ligand taking an indocyanine green derivative as a carrier as well as a preparation method and application of the ligand. When the ligand is chelated with paramagnetic metal ions, an NIR/MRI multi-mode contrast agent is obtained, when the ligand is chelated with radioactive metal ions, an NIR/PET multi-mode contrast agent is obtained, and the obtained contrast agents can be used for diagnosis of various tumors, especially liver cancer. Meanwhile, the contrast agents are good in water solubility and low in toxicity, mutual verification of multiple contrast modes is achieved, diagnosis information is enriched, diagnosis precision is improved, and a feasible novel contrast agent is provided for early diagnosis of tumors clinically.
NIR/MRI bimodal contrast agent, and preparation method and application thereof
-
Paragraph 0172-0180, (2021/07/24)
The invention discloses a near infrared imaging and nuclear magnetic resonance imaging (NIR)/MRI bimodal contrast agent, and a preparation method and application thereof. The NIR/MRI bimodal contrast agent is obtained by taking an optimized indocyanine green derivative as a carrier and connecting an MRI signal molecule. The contrast agent can be used for near-infrared imaging and also has an MRI imaging capability; and meanwhile, water solubility is good, toxicity is low, near-infrared and MRI images verify each other, diagnosis information is enriched, and the contrast agent has the potential of becoming a novel tumor contrast agent.